Engineered Cardiac Tissues Generated in the Biowire II: A Platform for Human-Based Drug Discovery.

Autor:	Feric NT; TARA Biosystems Inc, Alexandria Center for Life Sciences, New York, New York 10016., Pallotta I; TARA Biosystems Inc, Alexandria Center for Life Sciences, New York, New York 10016., Singh R; TARA Biosystems Inc, Alexandria Center for Life Sciences, New York, New York 10016., Bogdanowicz DR; TARA Biosystems Inc, Alexandria Center for Life Sciences, New York, New York 10016., Gustilo MM; TARA Biosystems Inc, Alexandria Center for Life Sciences, New York, New York 10016., Chaudhary KW; GlaxoSmithKline, Collegeville, Pennsylvania 19426., Willette RN; GlaxoSmithKline, Collegeville, Pennsylvania 19426., Chendrimada TP; GlaxoSmithKline, Collegeville, Pennsylvania 19426., Xu X; GlaxoSmithKline, Collegeville, Pennsylvania 19426., Graziano MP; TARA Biosystems Inc, Alexandria Center for Life Sciences, New York, New York 10016., Aschar-Sobbi R; TARA Biosystems Inc, Alexandria Center for Life Sciences, New York, New York 10016.
Jazyk:	angličtina
Zdroj:	Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2019 Nov 01; Vol. 172 (1), pp. 89-97.
DOI:	10.1093/toxsci/kfz168
Abstrakt:	Recent advances in techniques to differentiate human induced pluripotent stem cells (hiPSCs) hold the promise of an unlimited supply of human derived cardiac cells from both healthy and disease populations. That promise has been tempered by the observation that hiPSC-derived cardiomyocytes (hiPSC-CMs) typically retain a fetal-like phenotype, raising concern about the translatability of the in vitro data obtained to drug safety, discovery, and development studies. The Biowire II platform was used to generate 3D engineered cardiac tissues (ECTs) from hiPSC-CMs and cardiac fibroblasts. Long term electrical stimulation was employed to obtain ECTs that possess a phenotype like that of adult human myocardium including a lack of spontaneous beating, the presence of a positive force-frequency response from 1 to 4 Hz and prominent postrest potentiation. Pharmacology studies were performed in the ECTs to confirm the presence and functionality of pathways that modulate cardiac contractility in humans. Canonical responses were observed for compounds that act via the β-adrenergic/cAMP-mediated pathway, eg, isoproterenol and milrinone; the L-type calcium channel, eg, FPL64176 and nifedipine; and indirectly effect intracellular Ca2+ concentrations, eg, digoxin. Expected positive inotropic responses were observed for compounds that modulate proteins of the cardiac sarcomere, eg, omecamtiv mecarbil and levosimendan. ECTs generated in the Biowire II platform display adult-like properties and have canonical responses to cardiotherapeutic and cardiotoxic agents that affect contractility in humans via a variety of mechanisms. These data demonstrate that this human-based model can be used to assess the effects of novel compounds on contractility early in the drug discovery and development process. (© The Author(s) 2019. Published by Oxford University Press on behalf of the Society of Toxicology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu